Gilead (the same company that produces Truvada, the PrEP medication) said in interviews that it randomly chose $1,000 per pill, in effect, to see if insurers would pay it. Most insurers would because a) it was an FDA-approved treatment and b) because the drug results in cure in about 90% of the cases, the 12 weeks of treatment at $84,000 still ended up being less than the cost of a lifetime of managing the disease process of Hep C.
It wasn't until later that the cost of $1,400 for the 12 week supply was disclosed in an interview with one of the physicians involved in the development of the drug. That physician now works for the VA, so Gilead's retail price of the drug shocked him since he knew how much the drug actually cost to make.
Gilead plays another game that is increasingly common in the market: they provide "discount cards" that help cover copays or in some cases, result in a lowered price for some patients. They also provide the initial doses of the medication free to physicians so that the patient can get the first couple of days free before they discover the actual cost of the full 12 week treatment. This is the same strategy that they're using with PrEP which costs about $1300 per month and is partially covered by insurance.
The words "cost to make" on their face do not include research development.


























